Tumour Hospital of Liaocheng

Liaocheng, China

Tumour Hospital of Liaocheng

Liaocheng, China
SEARCH FILTERS
Time filter
Source Type

Liang H.-F.,Tumour Hospital of Liaocheng | Zhang X.-Z.,Liaocheng Peoples Hospital | Liu B.-G.,Liaocheng Peoples Hospital | Jia G.-T.,Liaocheng Peoples Hospital | Li W.-L.,Liaocheng Peoples Hospital
American Journal of Cancer Research | Year: 2017

Circular RNA (circRNA) is a key regulator in the development and progression of human cancers, however its role in breast cancer tumorigenesis is not well understood. The present study aims to investigate the expression profiles and potential modulation of circRNA on breast cancer carcinogenesis. Human circRNA microarray was performed to screen for abnormally expressed circRNA in breast cancer tissue. Results found circ-ABCB10, was significantly up-regulated in breast cancer tissue. And results were replicated in a larger sample size. In vitro, lossof- function experiments showed circ-ABCB10 knockdown suppressed the proliferation and increased apoptosis of breast cancer cells. Bioinformatics prediction program predicted the complementary sequence within circ-ABCB10 and miR-1271, which was validated by luciferase reporter assay. Finally, miR-1271 rescued the function of circ-ABCB10 on breast cancer cells, confirming the sponge effect of circ-ABCB10 on miR-1271. Overall, results identified a new functional circ-ABCB10 in breast cancer tumorigenesis, and reveal the important regulatory role of circ-ABCB10 through sponging miR-1271, providing a novel insight for breast cancer pathogenesis.


Lv R.,Tumour Hospital of Liaocheng | Feng Q.-L.,Tumour Hospital of Liaocheng | Li Y.-J.,Tumour Hospital of Liaocheng | Xu Y.-J.,Tumour Hospital of Liaocheng | Jia X.-Q.,Tumour Hospital of Liaocheng
Journal of Practical Oncology | Year: 2013

To analyze the therapeutic effect of medical imaging-guided intratumoral injection of ethanol combined with microwave for the treatment of recurrent malignant schwannoma. Eight patients with recurrent malignant schwannoma who could not be re-resected were injected with ethanol intratumorally under CT or ultrasound and then combined with microwave ablation. The improved clinical symptoms after treatment, the local tumor control effect and the long-term efficacy were observed. After treatment, the clinical symptoms in 8 patients were improved by varying degrees. The Karnofsky score was raised from 67.52 ± 10.50 before treatment to 85.33 ± 14.32 (P=0.013). Enhanced CT scan showed no tumor enhancement and the volume was gradually reduced from (34.65 ± 9.27) cm3 before treatment to (24.51 ± 6.32) cm3 (P=0.011) after six-month follow-up. The overall follow-up was 24 to 62 months. Six cases were surviving and 2 died and no obvious treatment-related complications were discovered. Ethanol injection combined with microwave ablation for the treatment of malignant schwannoma shows minimal invasion, slight complications and significant local efficacy and can be used as a supplementary treatment for patients with recurrent malignant schwannoma.


Objective To evaluate the efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia (BPH) in patients with high-risk comorbidities. Methods Seventy patients with BPH who showed poor oral drug efficacy and were medically fragile or unwilling to undergo operative therapy were enrolled in the study. They received ultrasound-guided transrectal ethanol injection and were followed up at 1, 3, 6, 12, and 24 months post-treatment. Volume and pathology of the prostate were observed. International prostate symptom score, quality of life, maximum urinary flow rate (Qmax), and postvoid residual volume were determined. The clinical complications were also recorded. Results After 24 months of treatment, prostate volume, international prostate symptom score, quality of life score, and postvoid residual of patients were significantly reduced when compared with the pretreatment values (55.9 ± 16.7 vs 46.8 ± 8.1 mL, 29.3 ± 6.7 vs 9.8 ± 2.4 points, 5.3 ± 1.7 vs 1.9 ± 0.7 points, and 130.8 ± 71.5 vs 25.9 ± 12.0 mL, respectively, P <.05). Qmax significantly increased to 15.3 ± 3.2 mL/s than the pretreatment Qmax of 4.7 ± 3.1 mL/s (P =.001). Four of 36 patients who received a high dose of ethanol developed liquefaction necrosis and urinary tract injury (2 patients each). However, the subsequent 34 patients received a reduced dose of ethanol and had no complications. Conclusion The minimally invasive technique of ultrasound-guided transrectal ethanol injections showed good efficacy with few complications for the treatment of patients with BPH and other high-risk comorbidities.


To evaluate the efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia (BPH) in patients with high-risk comorbidities.Seventy patients with BPH who showed poor oral drug efficacy and were medically fragile or unwilling to undergo operative therapy were enrolled in the study. They received ultrasound-guided transrectal ethanol injection and were followed up at 1, 3, 6, 12, and 24 months post-treatment. Volume and pathology of the prostate were observed. International prostate symptom score, quality of life, maximum urinary flow rate (Qmax), and postvoid residual volume were determined. The clinical complications were also recorded.After 24 months of treatment, prostate volume, international prostate symptom score, quality of life score, and postvoid residual of patients were significantly reduced when compared with the pretreatment values (55.9 16.7 vs 46.8 8.1 mL, 29.3 6.7 vs 9.8 2.4 points, 5.3 1.7 vs 1.9 0.7 points, and 130.8 71.5 vs 25.9 12.0 mL, respectively, P<.05). Qmax significantly increased to 15.3 3.2 mL/s than the pretreatment Qmax of 4.7 3.1 mL/s (P= .001). Four of 36 patients who received a high dose of ethanol developed liquefaction necrosis and urinary tract injury (2 patients each). However, the subsequent 34 patients received a reduced dose of ethanol and had no complications.The minimally invasive technique of ultrasound-guided transrectal ethanol injections showed good efficacy with few complications for the treatment of patients with BPH and other high-risk comorbidities.

Loading Tumour Hospital of Liaocheng collaborators
Loading Tumour Hospital of Liaocheng collaborators